Yahoo! Finance: OREX News

Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635 (PR Newswire)

Wed, 23 Dec 2009 23:05:00 Etc/GMT

Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that on December 23, 2009 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 64,000 shares of common stock to two new employees.

On Gaining More Impotence & Weightloss Drugs (at CNBC)

Wed, 23 Dec 2009 17:08:55 Etc/GMT

[video] Top 2010 Stocks Under $10 (at TheStreet.com)

Tue, 22 Dec 2009 20:00:00 Etc/GMT

[video] Top Stocks Under $10 for 2010 (at TheStreet.com)

Tue, 22 Dec 2009 20:00:00 Etc/GMT

UPDATE - Arena files for approval for weight loss drug (at Reuters)

Tue, 22 Dec 2009 18:38:34 Etc/GMT

Arena files for FDA approval of obesity drug (AP)

Tue, 22 Dec 2009 16:01:42 Etc/GMT

The first of a new class of obesity drugs moved one step closer to the market Tuesday, as Arena Pharmaceuticals Inc. said it filed for approval of its drug candidate lorcaserin.

OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (EDGAR Online)

Fri, 18 Dec 2009 22:24:08 Etc/GMT

[video] Top 2010 Stocks Under $10 (at TheStreet.com)

Thu, 10 Dec 2009 11:00:00 Etc/GMT

12 Years Of Patent Protection For Biologics Based Research And Development Creates Buying Opportunity In Biotech Stocks (Wall Street Transcript)

Sat, 28 Nov 2009 15:34:00 Etc/GMT

67 WALL STREET, New York - November 28, 2009 - The Wall Street Transcript has recently published its Q4 2009 Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Insider Buying Bodes Well For Orexigen (at Seeking Alpha)

Thu, 26 Nov 2009 10:21:49 Etc/GMT

Founder Scott Cook Sells $14.7M Worth of Intuit (TheStreet.com)

Wed, 25 Nov 2009 15:21:57 Etc/GMT

OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (EDGAR Online)

Tue, 24 Nov 2009 17:41:24 Etc/GMT

Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)

Tue, 24 Nov 2009 13:00:00 Etc/GMT

Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.

The Side Effect of Developing Obesity Drugs (at Motley Fool)

Mon, 23 Nov 2009 21:13:28 Etc/GMT

Poniard Finds Cash to Keep Lights On: BioBuzz (at TheStreet.com)

Mon, 23 Nov 2009 17:59:22 Etc/GMT

Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz (at TheStreet.com)

Mon, 23 Nov 2009 15:14:59 Etc/GMT

FDA Issues New Obesity Drug Heart Warning: BioBuzz (at TheStreet.com)

Mon, 23 Nov 2009 13:15:28 Etc/GMT

Four Senior Executives Join Orexigen(R) Therapeutics Management Team (PR Newswire)

Mon, 23 Nov 2009 13:00:00 Etc/GMT

Orexigen® Therapeutics, Inc. today announced that four senior executives have joined the organization, strengthening the management team that is driving the development of its obesity franchise.

Obesity and ED: Two Big Markets, One Tiny Company (at Minyanville.com)

Wed, 18 Nov 2009 20:20:00 Etc/GMT

Vivus is one stock to watch.

Obesity and ED: Two Big Markets, One Tiny Company (at Minyanville.com)

Wed, 18 Nov 2009 20:20:00 Etc/GMT